Exabis Library
Welcome to the e-CCO Library!
P704: Association between trough levels of vedolizumab and therapy outcome in a cohort of patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P704: Bifidobacterium longum species protect murine colitis through different activation repertoires of immune cells
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P704: The effect of antiTNFα and anti-integrin agents on liver steatosis in inlamatory bowel disease patients with non-alcoholic fatty liver disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P704: The impact of travel distance on disease outcomes in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P704: Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P705 Dietary practices and beliefs of patients with older-onset inflammatory bowel disease: A prospective UK study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P705: Incidence and risk factors of micronutrient deficiency in the patients with inflammatory bowel disease in Korea: folate, vitamin B12, 25-OH-vitamin D, ferritin
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P705: Peripheral arterial disease is associated with an increased risk of elderly-onset inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P705: Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomes
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P705: Switching from originator to biosimilar infliximab—real-world data from 18 months prospective follow-up of a single-centre IBD population
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P705: The effects of commonly consumed dietary fibres on the gut microbiome and its fibre fermentative capacity in adults with inflammatory bowel disease in remission
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P706 Adalimumab drug levels at secondary loss of response in Crohn’s disease; are we aiming high enough? A retrospective, international multi-centre study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P706: A distinct subset of tissue-resident Th17 cells expands in the inflamed intestines of Crohn’s Disease patients and responds to colitogenic bacteria
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P706: Caracterization of de novo inflammatory bowel disease (IBD) diagnosed in immigrants migrating from low to high prevalence areas of IBD: a case-control study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P706: Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P706: Monitoring asymptomatic patients with Crohn's disease: the role of intestinal ultrasound
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P706: Patient knowledge towards biological treatment in inflammatory bowel diseases: a cross-sectional survey
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P707 Anti-TNFα therapy has no effect on bone mineral density in younger patients with inflammatory bowel disease: A single-centre observational study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P707: 38 Weeks treatment of UC patients with different daily doses of mesalazine
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P707: Increasing abundance of faecalibacterium prausnitzii is associated with decreased intestinal inflammation in Crohn’s disease: A longitudinal study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM